Zynex Inc Stock Price, News & Analysis

Zynex, a medical technology firm, has appointed Donald Gregg as the new Vice President of Sales and Operations for its Monitoring Solutions Division. He is tasked with leading the development and marketing of the CM-1500 Blood Volume Monitor, which received FDA clearance in 2020. CEO Thomas Sandgaard expressed confidence in Gregg's ability to enhance product offerings and sales strategies. The division aims to set new standards for detecting internal bleeding. Gregg's extensive background includes roles at Smith Medical and Medtronic, where he achieved significant sales growth.

Zynex, Inc. (Nasdaq: ZYXI) has announced it will host its first quarter earnings investor webcast on April 29, 2021, at 2:15 p.m. MT (4:15 p.m. ET). The company specializes in non-invasive medical devices for pain management and rehabilitation. Participants can register through the provided link or dial in 10-15 minutes prior to the webcast. Founded in 1996, Zynex designs electrotherapy devices and has developed a proprietary NeuroMove device for stroke recovery.

Zynex, Inc. (NASDAQ: ZYXI) reported a remarkable 140% year-over-year order growth for Q1 2021. The company confirmed revenue estimates for the quarter between $23.0 million and $24.5 million, alongside an estimated Adjusted EBITDA loss of $0.5 million to $1.5 million. For the full year 2021, Zynex anticipates revenues between $135.0 million and $150.0 million, marking a 68% to 87% increase from 2020's revenue of $80.1 million. The company is actively expanding its sales team to promote its prescription-strength NexWave device as a safe alternative for pain management.

Zynex, Inc. (NASDAQ: ZYXI) has announced its relocation to a new corporate headquarters in Englewood, Colorado, expanding its space from 86,000 square feet to 110,754 square feet. The new lease, effective May 3, 2021, spans 84 months and includes an option for an additional 56,158 square feet. CEO Thomas Sandgaard highlighted competitive lease rates and significant rent credits that enhance the company's financial position. This move aligns with Zynex's growth in manufacturing and sales of non-invasive medical devices for pain management and rehabilitation.

Zynex, Inc. (NASDAQ: ZYXI) has initiated a $10.0 million share buyback program aimed at enhancing shareholder value. Announced on March 8, 2021, the program will commence immediately and conclude by September 8, 2021, or once the buyback limit is reached. Zynex's leadership, including President and CEO Thomas Sandgaard, expressed confidence in the company's growth prospects and stated that the current market valuation does not reflect its true value. The buybacks will be funded through existing cash and are expected to have no material impact on the company’s capital levels.

Zynex reported a remarkable 76% revenue increase for 2020, totaling $80.1 million. Fourth quarter revenue also surged by 81% to $25.6 million, with a net income of $1.8 million and adjusted EBITDA of $3.4 million. The company maintains a strong cash position with $39.2 million on hand. For 2021, Zynex projects revenue between $135 million and $150 million, indicating a potential growth of 68% to 87% compared to 2020. Despite anticipated challenges in Q1 due to seasonal factors, the company expects profitability to improve throughout the year.

Zynex, Inc. (Nasdaq: ZYXI), a leader in medical technology, announced an earnings webcast for Q4 and full-year 2020 on February 25, 2021, at 2:15 p.m. MT (4:15 p.m. ET). The webcast will cover their financial performance, although specific metrics were not disclosed in the PR. Stakeholders can register to attend the event online or via the provided dial-in numbers. Zynex specializes in non-invasive medical devices for pain management and rehabilitation.

Zynex, Inc. (NASDAQ: ZYXI) has promoted Anna Lucsok to Chief Operating Officer of Zynex Medical as of January 28, 2021, succeeding Joseph Papandrea. Lucsok, who previously served as Vice President of Reimbursement and Sales Operations, has extensive experience in healthcare operations and has significantly contributed to the company's sales and patient experience improvements. CEO Thomas Sandgaard expressed gratitude for Papandrea's contributions and optimism for Lucsok's leadership in driving growth and success in the company's operations.